Open AccessRecurrent epithelial ovarian cancer and hormone therapy
Author(s) -
Yoshihiko Yokoyama,
Hideki Mizunuma
Publication year - 2013
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v1.i6.187
Subject(s) - medicine , ovarian cancer , oncology , aromatase , adverse effect , hormone therapy , hormone receptor , aromatase inhibitor , estrogen , hormone , cancer , gynecology , breast cancer
The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase II clinical studies. Most of these studies were conducted in platinum-resistant recurrent ovarian cancer, and although complete response rates were not high, reported adverse events were low. If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.